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Abstract
OBJECTIVES: A retrospective database was developed by the European Society of Thoracic Surgeons, collecting patients submitted to
surgery for thymic tumours to analyse clinico-pathological prognostic predictors.
METHODS: A total of 2151 incident cases from 35 institutions were collected from 1990 to 2010. Clinical-pathological characteristics were
analysed, including age, gender, associated myasthenia gravis stage (Masaoka), World Health Organization histology, type of thymic
tumour [thymoma, thymic carcinoma (TC), neuroendocrine thymic tumour (NETT)], type of resection (complete/incomplete), tumour size,
adjuvant therapy and recurrence. Primary outcome was overall survival (OS); secondary outcomes were the proportion of incomplete
resections, disease-free survival and the cumulative incidence of recurrence (CIR).
RESULTS: A total of 2030 patients were analysed for OS (1798 thymomas, 191 TCs and 41 NETTs). Ten-year OS was 0.73 (95% conﬁdence
interval 0.69–0.75). Complete resection (R0) was achieved in 88% of the patients. Ten-year CIR was 0.12 (0.10–0.15). Predictors of shorter
OS were increased age (P < 0–001), stage [III vs I HR 2.66, 1.80–3.92; IV vs I hazard ratio (HR) 4.41, 2.67–7.26], TC (HR 2.39, 1.68–3.40) and
NETT (HR 2.59, 1.35–4.99) vs thymomas and incomplete resection (HR 1.74, 1.18–2.57). Risk of recurrence increased with tumour size
(P = 0.003), stage (III vs I HR 5.67, 2.80–11.45; IV vs I HR 13.08, 5.70–30.03) and NETT (HR 7.18, 3.48–14.82). Analysis using a propensity
score indicates that the administration of adjuvant therapy was beneﬁcial in increasing OS (HR 0.69, 0.49–0.97) in R0 resections.
CONCLUSIONS: Masaoka stages III–IV, incomplete resection and non-thymoma histology showed a signiﬁcant impact in increasing recur-
rence and in worsening survival. The administration of adjuvant therapy after complete resection is associated with improved survival.
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INTRODUCTION
Thymic malignancies are uncommon tumours, with an estimated
incidence of 2.5–3.2/106 people. Thymomas, thymic carcinomas
(TC) and neuroendocrine thymic tumours (NETT) are the three
most important histological categories.
The rarity of thymic tumours has limited so far the possibility
to set homogeneous management protocols as evidenced by a
recent survey from the European Society of Thoracic Surgeons
(ESTS) [1]. For this reason, the identiﬁcation of prognostic predic-
tors is of utmost importance to guide the clinician to the most
appropriate therapeutic treatment in these rare tumours. A
recent review [2] of the available literature evaluating studies
reporting multivariable analyses of prognostic factors conﬁrmed
the limitations in our current knowledge about prognostic factors
in thymic tumours.
Collaborative retrospective databases offer the opportunity to
collect a large series of patients in a relatively short time period,
and for this reason, they are helpful in rare diseases such as thymic
malignancies.
The ESTS retrospective database project was launched in 2011
among ESTS members to collect data of patients submitted to
© The Author 2014. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.
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surgical resection of thymic tumours from 1990 to 2010.
Follow-up data collection was closed in December 2011. The aim
of the present study was to investigate, using the largest database
of thymic malignancies ever collected, several clinical-pathological
prognostic predictors of incomplete resection, survival and recur-
rence that have been previously tested with conﬂicting results in
smaller observational studies.
MATERIALS ANDMETHODS
ESTS is a thoracic surgical organization open to European and
non-European members around the world. An enquiry was sent
to all ESTS members to ask for participation to the thymic data-
base project and to send their data. Thirty-ﬁve institutions
responded and joined the project: 27 from Europe, 3 from Asia
and 5 from USA/Canada. Institutional Review Board approval was
obtained at each institution.
The data ﬁelds included demographics, presence of myasthenia
gravis (MG), histology [2004 World Health Organization (WHO)
classiﬁcation [3]], tumour size (continuous), stage according to
Masaoka [4], completeness of resection, administration of induction
or adjuvant treatment, type of surgical procedure, data for survival
analysis, cause of death, recurrence, year of surgery and mean
number of patients provided by the centres/year (≤4, 5–9, ≥10).
Patients operated on or before 2004 were reclassiﬁed at each
centre using the latest WHO histological classiﬁcation [3]. In-
formation about the site of recurrence was not sufﬁcient to
include this covariate in the predictor analysis.
Overall, data on 2244 patients were collected. Of these, 58
patients with not–otherwise-speciﬁed lesions, 19 with undeter-
mined tumours and 16 with insufﬁcient data were excluded, and
the remaining 2151 patients form the basis of our report.
Study outcomes
Primary outcome was overall survival (OS) calculated from the
date of surgery to the date of death from any cause. Secondary
outcomes were the proportion of incomplete resections (micro-
scopically or macroscopically), the disease-free survival (DFS) cal-
culated from the date of surgery to the date of recurrence or
death from any cause, and the cumulative incidence of recurrence
(CIR) calculated from the date of surgery to the date of recurrence.
In order to rule out a potential bias between patients with and
without information about recurrence (missing recurrence date or
recurrence status) out of the total of R0 resections, we compared
OS curves of the two groups. The difference between the curves
was not signiﬁcant [HR 1.19 95% conﬁdence interval (CI) 0.88–
1.60; P = 0.25]. We therefore assumed that no signiﬁcant bias exists
between the two populations.
Statistical analysis
OS and DFS were estimated by the Kaplan–Meier product-limit
method. CIR was estimated considering death from any cause as a
competing event. To account for the heterogeneity across centres,
factors associated with OS and DFS were investigated using Cox
proportional hazard models with shared frailty. CIR was analysed
with proportional hazard frailty models for the subdistribution [5]
including the same variables considered for the OS analysis.
Factors associated to incomplete resection were investigated
using mixed-effect logistic regression models, considering the
centre as random effect.
The effect of adjuvant therapy on OS was investigated in patients
after R0 resection and by subgroups. In order to adjust this non-
randomized comparison and to reduce the loss of power in the
subgroup analyses, a propensity score for the likelihood of receiving
adjuvant therapy was calculated from eight covariates: age, gender,
stage, tumour size, histology, MG, year of intervention and mean
annual number of resections. Multivariable Cox proportional
hazard models with shared frailty (for centre heterogeneity) were
estimated including as predictor the adjuvant therapy along with
the propensity score. Effect modiﬁcations by subgroups were evalu-
ated by including in the models an interaction term between the
covariate indicating the adjuvant therapy and the subgroup covari-
ate of interest, adjusting for propensity score.
In all models ﬁtted in this study, missing data were multiple
imputed using the method of chained equations [6]. Combined
estimates were obtained from ﬁve imputed datasets.
The statistical analysis was performed using STATA (version 11.1)
(ice command for multiple imputation) and R (version 2.15.1)
(cmprsk and crrSC packages for the competing event analyses).
RESULTS
The median number of patients submitted by each institution was
45 [interquartile range (IQR) 24–73, range 8–257]; 20 institutions
(57%) reported <60 cases, 8 (23%) reported 60–99 cases and 7
(20%) reported at least 100 cases. The majority of institutions per-
formed a follow-up schedule based on a 3- to 6-month computed
tomography (CT) scan for the ﬁrst 3 years, followed by annual CT
scan lifelong. In most centres, more aggressive thymic tumours (TC
and NETT) received a more strict imaging (CT) surveillance. The
median follow-up time of surviving patients was 48 months (IQR
21–90). Fixed at 31 December 2011, the end of the follow-up data
collection, the completeness of follow-up for the study was 73%.
Study ﬂow of the patient population and patient
characteristics
Figure 1 shows the study ﬂow of the 2151 patients in the database;
2030 had sufﬁcient information for OS analysis and 1325 for DFS
and CIR analysis.
Table 1 shows the patient characteristics and the number and
percentages of missing information for the 2030 patients with suf-
ﬁcient information for OS analysis. Of these, there were 1798
thymomas, 191 TCs and 41 NETTs.
A complete resection was achieved in 1709 patients (88%).
The resectability rates were 99, 92, 78 and 53% for stages I, II, III
and IV, respectively. The rates were 97, 97, 91, 85, 77, 72 and 69%
for types A, AB, B1, B2, B3, TC and NETT
Induction therapy (mostly chemotherapy, 71%) was adminis-
tered in 239 patients, of whom 186 (80%) were at stage III/IV; ad-
juvant therapy was administered in 853 patients and consisted of
radiotherapy (n = 566), chemotherapy (n = 44) and combined
chemo/radiotherapy (n = 243).
Frequency of study end points
Three hundred and twenty-four patients died during the follow-
up. Ninety patients had recurrence out of 1325 R0 patients, with
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complete information about the recurrence status. Two hundred
and fourteen patients had either recurrence or died out of the
1325 patients evaluated for DFS and CIR analysis.
Predictors of incomplete resection
In 1709 patients with complete resection, recurrence occurred in
141 cases (8%); it increased with stage (stages I 3%, II 4%, III 22%,
IV 40%) and histology (A 3%, AB 5%, B1 8%, B2 11%, B3 14%, TC
30%, NETT 37%).
Among the different examined clinico-pathological variables,
the probability of an incomplete resection is higher in male
patients (adjOR 1.61, 95% CI 1.18–2.20, P = 0.003); it increases with
tumour size (adjOR 1.10 [per 1 cm increase], 95% CI 1.01–1.21,
P = 0.031), while it decreases in the presence of MG (adjOR 0.55,
95% CI 0.37–0.81, P = 0.002). With respect to A-AB-B1 thymoma,
the probability of an incomplete resection is higher in B2-B3
thymoma (adjOR 5.91, 95% CI 4.02–8.70, P < 0.001), TC (adjOR
10.46, 95% CI 6.22–17.59, P < 0.001) and NETT (adjOR 7.77, 95%
CI 3.45–17.51, P < 0.001).
Overall survival and disease-free survival analyses
Figure 2 reports the overall time-to-event curves for the different
end points (OS, DFS and CIR). Five- and 10-year OS rates were
0.85 (95% CI 0.83–0.86) and 0.73 (95% CI 0.69–0.75), and DFS
rates were 0.84 (95% CI 0.82–0.87) and 0.70 (95% CI 0.65–0.74).
Thirty-day mortality was 1% (21 cases).
Table 2 shows the analysis of OS predictors. The results of the
DFS analysis paralleled those of OS analysis and were not
reported. The risk of mortality increases with age [adjHR (per 5
year increase) 1.19, 95% CI 1.14–1.24, P < 0.001] and with stage (III
vs I adjHR 2.66, 95% CI 1.80–3.92, P < 0.001; IV vs I adjHR 4.41,
95% CI 2.67–7.26, P < 0.001). The mortality risk is also higher for
TC (adjHR 2.39, 95% CI 1.68–3.40, P < 0.001), NETT (adjHR 2.59,
95% CI 1.35–4.99, P = 0.004) and after incomplete resection
(adjHR 1.74, 95% CI 1.18–2.57, P = 0.007); a weak trend towards an
increased risk was found in males (adjHR 1.25, 95% CI 0.99–1.58,
P = 0.06). No evidence of a major effect modiﬁcation by histology
categories (thymoma, TC and NETT) was found for the evaluated
prognostic factors (Table 3).
Recurrence analysis
Cumulative incidence of recurrence was 0.05 (95% CI 0.04–0.07),
0.08 (95% CI 0.06–0.09) and 0.12 (95% CI 0.10–0.15) at 3, 5 and 10
years, respectively (Fig. 2).
Signiﬁcant predictors of higher risk of recurrence included
(Table 4) young age, non-MG status, increased tumour size, stages
III and IV, NETT tumours and the most recent years of intervention
(using as reference the earliest period, 1990–1995).
Adjuvant therapy
Radiation doses and chemotherapeutic regimens for adjuvant
treatments varied among the centres. In general, a total dose of
40–60 Gy was employed for radiotherapy, while cisplatin-based
regimens (mostly cisplatin/doxorubicin/cyclophosphamide-CAP,
or cisplatin/doxorubicin/cyclophosphamide/vincristine-ADOC) were
uniformly used. The analysis was undertaken on the subgroup of
patients receiving adjuvant therapy after R0 resection. Complete
information was available in 1662 patients out of 1709 R0 resec-
tions (Fig. 1). Adjuvant therapy was more frequently administered
in younger patients (median age 54 vs 57) and in advanced stages
(stage I 75/646, 12%; II 316/612, 52%; III 217/295, 74%; IV 56/91,
62%); the administration was also different according to histology
(A-AB-B1 256/920, 28%; B2-B3 326/599, 54%; TC 78/116, 67%;
NETT 16/27, 59%) (Table 5). The subgroup analysis was undertaken
using a Cox model with shared frailty adjusted for propensity
score. Results are reported in Fig. 3 as forest plot. The overall effect
Figure 1: Study ﬂow diagram of the patient population for analysis of predictors.
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of adjuvant therapy on OS was signiﬁcantly beneﬁcial (HR 0.69,
95% CI 0.49–0.97). No strong evidence of an effect modiﬁcation
by speciﬁc subgroup was found. The overall effect of radiotherapy
(alone or with chemotherapy) was nearly identical as in the whole
adjuvant group (HR 0.66, 95% CI 0.46–0.94).
DISCUSSION
The results of our cohort study on patients submitted to surgical
resection for thymic malignancies indicate that (i) independent
negative predictors of OS were increased age, high Masaoka
stages (III/IV), TC, NETT and incomplete resection; (ii) similar pre-
dictors for DFS were observed; (iii) adjusted predictors of in-
complete resection were male gender, increased tumour size,
non-MG status, high-risk thymomas (WHO B2/B3), TC and NETT;
(iv) the incidence of recurrence increases with the length of the
follow-up. Independent predictors of recurrence were young age,
non-MG status, increased tumour size, high Masaoka stages (III/
IV) and NETT and (v) exploratory analysis indicates that the admin-
istration of adjuvant therapy after complete resection was effective
in increasing OS without strong differences among subgroups.
Our analysis showed that several variables are independent pre-
dictors of OS, incomplete resection and recurrence, conﬁrming
previous smaller observational studies.
Masaoka stage
The clinico-pathological staging system proposed by Masaoka has
been repeatedly reported to impact survival and recurrence [7–9];
this is conﬁrmed by our study. Previous reports included stages I
and II in the same survival category, as the differences between
them were not crucial. In the present study, stages I and II pre-
sented similar adjusted hazard ratios, supporting evidence for a
redeﬁnition of their identities. In the absence of an ofﬁcially
recognized staging system, therefore, Masaoka stage remains the
most reliable way to stage thymic tumours.
Complete resection
In our analysis, macro- and microscopic complete resection (R0)
resulted an independent prognostic factor conﬁrming previous
reports [9, 10]. This variable was clearly associated with stage and it
was strongly prognostic of OS and DFS. An aggressive surgical
Table 1: Patient characteristics (n = 2030)
Missing information
Age, median (IQR) 56 (45;67) 3 (<1%)
Males 1042 (51%) 1 (<1%)
Myasthenia gravis 629 (35%) 243 (12%)
T size, median (IQR) 6 (4;7) 527 (26%)
Masaoka stage
1 672 (34%) 34 (2%)
2 699 (35%)
3 410 (21%)
4 215 (11%)
Diagnosis
Thymoma WHO A-AB-B1 1018 (50%) 0 (0%)
Thymoma WHO B2-B3 780 (38%)
Thymic carcinoma 191 (9%)
NETT 41 (2%)
Complete resections (R0) 1709 (88%) 80 (4%)
Intervention period
1990–1995 176 (9%) 0 (0%)
1996–2001 395 (19%)
2002–2007 858 (42%)
2008–2011 601 (30%)
Mean number of patients treated yearly by centre
≤4 [19 (54%) centres] 532 (26%) 0 (0%)
5–9 [11 (31%) centres] 680 (33%)
≥10 [ 5 (14%) centres] 818 (40%)
Induction therapy 239 (13%) 154 (8%)
CT alone 170 (9%)
RT alone 12 (1%)
CT and RT 57 (3%)
Adjuvant therapy 853 (44%) 76 (4%)
CT alone 44 (2%)
RT alone 566 (29%)
CT and RT 243 (12%)
Data are n (%) unless otherwise indicated. Percentages are calculated
on the basis of available data for each characteristics.
CT: chemotherapy; NETT: neuroendocrine thymic tumour;
RT: radiotherapy.
Figure 2: Curves of time-to-event end points.
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approach with en bloc removal of the neighbouring organs was
recommended to achieve complete resection [11], and this strat-
egy is supported by our ﬁndings.
Recurrence
Recurrence has a distinct signiﬁcance in thymic tumours. It may
occur late in the course of the disease, particularly in early-stage
tumours. Patients with a recurrence may live for many years owing
to the indolent behaviour of most thymomas, and the possibility of
reresection and multimodality treatments may signiﬁcantly prolong
survival in these patients [12, 13]. Our study indicates that the risk
of recurrence increases with time. This ﬁnding corroborates some
evidence in smaller studies that lifelong surveillance is warranted
after thymic malignancy resection. Recurrence was correlated
with advanced stage, increased tumour size and NETT histology.
Recurrence was also a robust negative prognostic factor for OS.
Table 2: Analysis of overall survival predictors. Cox proportional hazard model with shared frailty. (n = 2030)
Univariable analysis Multivariable analysisa
HR (95% CI) P HR (95% CI) P
Age (continuous, per 5 years increase) 1.16 (1.11–1.21) <0.001 1.19 (1.14–1.24) <0.001
Male 1.29 (1.03–1.62) 0.025 1.25 (0.99–1.58) 0.060
Myasthenia gravis 0.68 (0.51–0.89) 0.005 1.11 (0.84–1.48) 0.451
T size (continuous, per 1 cm increase) 1.07 (1.03–1.11) 0.001 1.04 (1–1.09) 0.073
Masaoka stage
1 (Ref) 1 – 1 –
2 1.38 (0.96–2.00) 0.084 1.09 (0.75–1.60) 0.655
3 3.58 (2.51–5.13) <0.001 2.66 (1.80–3.92) <0.001
4 7.43 (5.16–10.70) <0.001 4.41 (2.67–7.26) <0.001
Diagnosis
Thymoma WHO A-AB-B1 (Ref) 1 – 1 –
Thymoma WHO B2-B3 1.40 (1.07–1.82) 0.013 1.09 (0.82–1.46) 0.553
NETT 4.76 (2.55–8.87) <0.001 2.59 (1.35–4.99) 0.004
Thymic carcinoma 4.49 (3.27–6.15) <0.001 2.9 (1.68–3.40) <0.001
R status (R+ vs R0) 3.87 (2.82–5.30) <0.001 1.74 (1.18–2.57) 0.007
Year of intervention
1990–1995 (Ref) 1 – 1 –
1996–2001 1.25 (0.83–1.86) 0.282 1.09 (0.73–1.62) 0.690
2002–2007 1.44 (0.93–2.23) 0.099 1.05 (0.68–1.64) 0.816
2008–2011 1.27 (0.71–2.27) 0.427 1.07 (0.60–1.94) 0.812
Mean number patients (yearly)
≤4 (Ref) 1 – 1 –
5–9 1.09 (0.55–2.17) 0.797 1.75 (0.89–3.44) 0.102
≥10 0.64 (0.28–1.50) 0.309 0.92 (0.41–2.06) 0.838
NETT: neuroendocrine thymic tumour.
aAll effects were unadjusted for T size, whereas T size effect was unadjusted for Masaoka stage.
Table 3: Analysis of overall survival predictors by histology categories of thymic malignancies (thymoma, thymic carcinoma and
NETT). Cox proportional hazard model with shared frailty
Thymoma WHO
A-AB-B1
Thymoma WHO B2-B3 NETT Thymic carcinoma Interaction,
P
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Age (continuous, per 5
years increase)
1.22 (1.13–1.32) <0.001 1.17 (1.09–1.26) <0.001 1.15 (0.92–1.45) 0.220 1.18 (1.09–1.29) <0.001 0.852
Male 1.62 (1.11–2.38) 0.013 1.00 (0.69–1.46) 0.987 1.54 (0.39–6.07) 0.540 1.18 (0.73–1.89) 0.502 0.345
Myasthenia gravis 1.19 (0.76–1.85) 0.446 1.07 (0.72–1.60) 0.734 1.99 (0.26–15.41) 0.507 0.99 (0.49–1.98) 0.975 0.903
Tumour size (per 1 cm
increase)
1.06 (0.98–1.14) 0.135 1.05 (0.97–1.14) 0.199 1.01 (0.84–1.21) 0.957 1.02 (0.92–1.13) 0.699 0.899
Masaoka stage
1 (Ref) 1 – 1 – 1 – 1 – 0.690
2 1.32 (0.83–2.11) 0.243 0.78 (0.39–1.56) 0.480 1.12 (0.24–5.29) 0.883 1.07 (0.28–4.11) 0.921
3 2.13 (1.23–3.72) 0.007 2.87 (1.59–5.19) <0.001 2.30 (0.31–17.14) 0.412 2.88 (0.82–10.15) 0.100
4 4.37 (2.16–8.85) <0.001 5.17 (2.48–10.77) <0.001 4.37 (2.16–8.85) <0.001 3.69 (1.05–13.04) 0.042
R status (R1-R2 vs R0) 1.39 (0.73–2.63) 0.317 1.85 (1.12–3.04) 0.017 1.68 (0.49–5.74) 0.407 1.91 (0.97–3.76) 0.061 0.874
NETT: neuroendocrine thymic tumour.
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Histology
The current WHO classiﬁcation of thymic malignancies [3]
includes two categories: thymoma and TC; each one is further
divided into subtypes: 5 for thymoma and 11 for TC, including
NETT. TC and NETT have been reported to portend a worse prog-
nosis than thymomas [14–16]. In our study, NETT and TC were
strong predictors of reduced OS, DFS and of increased recurrence.
The prognostic signiﬁcance of the different thymoma subtypes
has not been conﬁrmed, and a few studies showed that it is pri-
marily related to the worse outcome of B3 tumours. Further, the
histological differentiation between B3 and TC is difﬁcult [17], with
a reported wide interobserver variability. In the present analysis,
high-risk thymomas (B2/B3) did not signiﬁcantly differ from
low-risk thymomas (A/AB/B1) for OS, DFS and recurrence, al-
though B2-B3 thymomas showed an increased risk of being asso-
ciated with incomplete resection. However, we are aware that the
lack of a central review of the pathology specimens in the present
series should be taken into account in the interpretation of the
obtained results.
Tumour size
The prognostic signiﬁcance of tumour size has been investigated in
thymic neoplasms, and smaller tumours were generally found to be
associated with improved survival and decreased risk of recurrence
[18]. However, the size thresholds that have been used in these
studies were somehow arbitrary. In the present study, we consid-
ered tumour size measured as the largest diameter on the surgical
specimen as continuous variable. Our analysis indicates that
increased tumour size was not a signiﬁcant predictor of either OS or
DFS, although it was found to increase the risk of recurrence and of
incomplete resection. This ﬁnding may be taken into consideration
in the indication of the follow-up schedule of these patients.
Myasthenia gravis
The role of MG has been addressed in several studies [19]; some
authors speculate that MG patients are different from non-MG
patients [20]. Our results somehow differ from these series, indi-
cating that the presence of MG has no impact on OS and DFS.
Non-MG patients, however, are at signiﬁcantly higher risk of re-
currence and of receiving incomplete resections. Although
adjusted for other covariates, this ﬁnding might be explained by
the more strict surveillance of MG patients leading to earlier
thymoma detection.
Induction therapy
Administration of induction therapy has been suggested to
improve resectability and survival and to decrease recurrence.
Retrospective studies [21, 22] showed an encouraging pooled
5-year OS of 78% with a complete resection rate of 72% in locally
advanced stages III–IVa thymic tumours, considerably higher than
historical series using upfront surgery. Based on these studies,
therefore, induction therapy is customarily performed in patients
with tumours deemed unresectable at initial surgical evaluation.
In the present study, an exploratory analysis of our data indicated
a strong biased selection of patients receiving induction treatment
that we could not control with the available information, thus
preventing the possibility to obtain an unbiased estimate of its
efﬁcacy.
Table 4: Cumulative incidence of recurrence. Proportional
hazard frailty models for the subdistribution on R0 patients
(N = 1325)
HR (95% CI)a P
Age (continuous, per 5 years increase) 0.91 (0.84–1.00) 0.039
Male 0.81 (0.55–1.19) 0.286
Myasthenia gravis 0.57 (0.33–0.98) 0.042
T size (continuous, per 1 cm increase) 1.16 (1.09–1.24) 0.003
Masaoka stage
1 (Ref) 1 –
2 1.46 (0.72–2.95) 0.288
3 5.67 (2.80–11.45) <0.001
4 13.08 (5.70–30.03) <0.001
Diagnosis
Thymoma WHO A-AB-B1 (Ref) 1 –
Thymoma WHO B2-B3 1.22 (0.67–2.20) 0.515
NETT 7.18 (3.48–14.82) <0.001
Thymic carcinoma 1.50 (0.64–3.49) 0.349
Year of intervention
1990–1995 (Ref) 1 –
1996–2001 9.43 (2.82–31.51) <0.001
2002–2007 10.92 (3.32–35.92) <0.001
2008–2011 8.18 (1.49–44.77) 0.015
Mean number patients (yearly) treated yearly by centre
≤4 (Ref) 1 –
5–9 1.01 (0.41–2.46) 0.984
≥10 1.08 (0.56–2.09) 0.820
NETT: neuroendocrine thymic tumour.
aAll effects were unadjusted for T size, whereas T size effect was
unadjusted for Masaoka stage.
Table 5: Patients characteristics according to the adminis-
tration of adjuvant therapy (R0 patients; n = 1662)
na Adjuvant therapy
administration
P*
No
(n = 986)
Yes
(n = 676)
Age, median (IQR) 1659 57 (46;68) 54 (44;64) <0.001
Males 1661 464 (47%) 368 (54%) 0.003
Myasthenia gravis 1491 322 (36%) 234 (39%) 0.229
T size, median (IQR) 1270 6 (4;7) 5 (4;6) 0.015
Masaoka stage
1 1644 571 (58%) 75 (11%) <0.001
2 296 (30%) 316 (48%)
3 78 (8%) 217 (33%)
4 35 (4%) 56 (8%)
Diagnosis
Thymoma WHO
A-AB-B1
1662 664 (67%) 256 (38%) <0.001
Thymoma WHO
B2–B3
273 (28%) 326 (48%)
Thymic carcinoma 38 (4%) 78 (12%)
NETT 11 (1%) 16 (2%)
NETT: neuroendocrine thymic tumour.
aAnalysis performed on the R0 patients with appropriate information
on the administration of adjuvant therapy and on the characteristics of
interest.
*P-values based on Mann–Whitney U-test and χ2 test for continuous
variables and categorical variables, respectively.
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Adjuvant therapy
Adjuvant treatment, mostly in the form of radiotherapy or com-
bined chemoradiotherapy, is currently administered in up to 60%
of the patients with invasive thymic tumours [1]. This attitude,
however, is based on several historical series, and its real impact
on survival and recurrence is still debated with no consistent evi-
dence having emerged so far. Kondo et al. [23] found that prophy-
lactic postoperative radiotherapy (PORT) neither prevented
recurrence nor increased survival after complete resection of
stages II–IV thymic tumours. In a large study based on the surveil-
lance epidemiology and end results database, Forquer et al. [24]
found on all-stage thymic tumours (thymoma and thymic carcin-
omas) that PORT had no or even detrimental effect on local
disease (Masaoka I), and a beneﬁcial overall effect on OS in
regional disease (stages II–III). Importantly, however, no survival
differences were observed after ‘extirpative’ (i.e. R0) surgery.
Finally, in a meta-analysis of retrospective studies from 1981 to
2008, Korst et al. [25] found no survival advantage for the use of
PORT after complete resection of stages II–III thymomas. The bulk
of evidence so far indicates that there is no convincing evidence
of a consistent survival advantage of the use of PORT after com-
plete resection of all-stage thymomas. In our study, the analysis of
the prognostic effect of adjuvant therapy after complete resection
was performed using a propensity score approach, minimizing the
bias resulting from unbalanced confounding factors and adjusting
the comparison for a large number of covariates in the subgroup
analyses. Our results indicate that adjuvant therapy provides
an overall beneﬁcial effect on OS, without a strong evidence of an
effect modiﬁcation by speciﬁc subgroup. Our ﬁnding may there-
fore support the need for further prospective trials about the role
of adjuvant treatment in thymic malignancies
The present study has several strengths and limitations. The
main strength is that it is based on the largest database of patients
with thymic tumours ever collected. The participating institutions
used a homogeneous staging system and histological classiﬁca-
tion. Several limitations result from the collection of data from
centres of different volume activity, expertise and geographic
areas and from the lack of a central review of pathology reports.
Also, the follow-up was not complete for all patients, and the
person-time at risk available for the OS analysis accounted for the
73% of the expected follow-up. Finally, in 15% of R0 recurrent
patients, we had no information about the recurrence date, result-
ing in a loss of statistical power of the analysis, and a consequent
theoretical underestimate of the CIR.
In conclusion, despite the previously reported limits, this study
on thymic tumours is of interest for its conﬁrmatory results about
the prognostic role of several factors, for the evidence of the
efﬁcacy of the current standard of care and because it provides
suggestions for further investigational studies.
Figure 3: Forest plot of subgroup analysis for adjuvant vs no adjuvant therapy comparison, adjusted for propensity score (OS). Cox model proportional hazard models
with shared frailty. Only R0 patients with available information on adjuvant therapy (n = 1662).
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